Improving Time-in-Range in Type 1 Diabetes: Projecting the Clinical and Cost Implications of Automated Insulin Delivery
Authors' conclusion
Long-term projections for England suggested that a 10-percentage point increase in TIR reduced diabetic complications in PwT1D, thereby reducing spending on complication treatment. Improvements were seen across baseline TIR levels but were disproportionately accrued in those with lower baseline TIR.
Study context
- Population
- Simulated cohort of people with T1D; baseline data from a National Institute for Health and Care Excellence economic assessment
- Comparison
- 10-percentage point time in range (TIR) increase vs constant TIR
- Outcome
- Cumulative incidence of complications
- Follow-up
- 20 years
Methodological detailshealth economic analysis, IQVIA CORE Diabetes Model, 20-year projection, English public health care system perspective, sensitivity analyses
- Health economic analysis
- IQVIA CORE Diabetes Model
- 20-year projection
- English public health care system perspective
- Sensitivity analyses
Main finding
As reported in the abstract
Reduction in ophthalmic complications with 10-point TIR increase
15.6%-53.0%
Reduction in renal complications
8.8%-47.1%
Reduction in neuropathic complications
8.1%-33.5%
Reduction in cardiovascular complications
10.1%-17.6%
Further findings
Life expectancy and quality-adjusted life expectancy (QALE) · 20 years
- Life expectancy gain
- 0.031-0.051 years
- QALE gain
- 0.056-0.143 quality-adjusted life-years
- Higher gains for lower baseline TIR
Total projected costs vs constant TIR · 20 years
- Total cost reduction, driven by reduced complication costs
- 7.5%-9.9%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →